Do Wegovy and Mounjaro cause muscle loss?

Wegovy (semaglutide) and Mounjaro (tirzepatide) are FDA-approved injectable medications prescribed for chronic weight management. They work by mimicking gut hormones — GLP-1 in Wegovy’s case, and both GLP-1 and GIP in Mounjaro’s — to reduce appetite, slow digestion, and support significant fat loss. What they are not is a selective fat-melting solution. When the body loses weight through any method, it loses a mixture of fat and lean tissue, and GLP-1 medications are no exception.

The question of whether these medications cause muscle loss is one of the most common concerns we hear at our West Palm Beach clinic — from patients who are already on them, from those considering them, and from people planning a procedure after reaching their weight goal.

This post answers it directly, with the numbers the clinical trials actually produced.

What does “muscle loss” actually mean on GLP-1 medications?

Not all weight loss is fat loss — and that distinction matters. When you lose weight, your body draws from both fat stores and lean tissue, which includes muscle, water, and connective tissue. The proportion of each depends on how fast you’re losing, what you’re eating, and how much you’re moving.

Semaglutide and tirzepatide do not directly cause muscle wasting. Some lean-mass reduction can occur during meaningful weight loss, but clinical trials consistently show that most weight lost is fat, not muscle. The more precise way to frame it: these medications accelerate weight loss, and faster weight loss tends to carry a slightly higher lean mass component than very gradual loss — not because the drug attacks muscle, but because the body is losing weight at a rate that requires it to draw from multiple sources.

Understanding this distinction protects you from both unnecessary alarm and from ignoring something genuinely worth managing.

Read more:

👉 How much weight can you lose on GLP-1 injections?

What the clinical trials show for Mounjaro (tirzepatide)

In the SURMOUNT-1 DXA sub-study — a rigorous body composition analysis of 160 participants — tirzepatide produced a 21.3% mean reduction in total body weight, a 33.9% reduction in fat mass, and a 10.9% reduction in lean mass at 72 weeks. Put plainly: for roughly every 4 pounds lost, approximately 3 came from fat and 1 from lean tissue.

Participants taking tirzepatide achieved an approximately three times greater reduction in fat mass than in lean mass, a ratio that compares favorably to what is typically observed with bariatric surgery.

That 25% lean mass contribution is meaningful, particularly for patients who are already lighter or older, where baseline muscle mass may be lower to begin with. It is not a reason to avoid the medication — but it is a reason to manage it proactively.

What the data shows for Wegovy (semaglutide)

In the STEP UP scan sub-study, 55 participants underwent detailed body MRI scans before and after treatment with higher-dose Wegovy. Around 84% of the weight they lost was fat. Their muscle mass fell by about 10% from the start, though their muscle strength did not decline at the same rate.

That last detail — strength holding while mass drops slightly — is clinically relevant. It suggests that some of the lean mass figure captured by scans reflects water and glycogen shifts rather than pure contractile muscle fiber loss. Still, a 10% lean mass reduction warrants attention, especially over a longer treatment period.

Is Mounjaro worse for muscle than Wegovy?

This is where recent real-world data adds nuance. A study published on medRxiv found that people on tirzepatide lost about 1.1% more lean body mass than those using semaglutide in the first three months, rising to 2% more lean body mass loss by 12 months. The researchers and commenting physicians noted this is not entirely surprising: tirzepatide is generally more potent, and with greater overall weight loss, a higher degree of lean mass loss tends to follow.

The takeaway is proportional, not absolute. Mounjaro produces more weight loss overall — trial data shows Mounjaro produces roughly 20–22% weight loss versus approximately 15% for Wegovy — so the lean tissue loss figure is larger in absolute terms, but the ratio of fat-to-lean lost remains similar. Neither medication selectively destroys muscle; both produce the mixed-tissue loss pattern consistent with meaningful caloric deficit.

	Wegovy (semaglutide)	Mounjaro (tirzepatide)
Primary mechanism	GLP-1 receptor agonist	Dual GLP-1 + GIP agonist
Mean weight loss (trials)	~15%	~20–22%
Fat mass reduction	~84% of loss (STEP UP MRI)	~75% of loss (SURMOUNT-1 DXA)
Lean mass reduction	~10% of baseline	~10.9% of baseline
Lean mass loss vs. comparator	Lower absolute	Slightly higher absolute (more total loss)

Read more:

👉 What is the difference between semaglutide and tirzepatide?

Why does it matter and who should be most aware?

Muscle does more than most people realize. It drives your resting metabolic rate, supports joint stability, shapes your physical appearance, and predicts long-term weight maintenance. When lean mass drops without a plan to rebuild it, the risk of weight regain after stopping the medication rises — and the body’s ability to process fat efficiently declines.

Research presented at ENDO 2026, the Endocrine Society’s annual meeting, found that people losing weight on GLP-1 medications actually became significantly less physically active during treatment — the opposite of what most patients and clinicians expected. Reduced activity on top of caloric restriction amplifies lean tissue loss. This is not an argument against the medications; it is an argument for pairing them with a plan.

Patients who are particularly attentive to this dynamic include:

1. Women over 40 — natural muscle mass decline accelerates in this group, making any additional lean loss more impactful
   
2. Patients planning body contouring procedures — the amount and distribution of remaining fat after GLP-1 treatment affects surgical candidacy and outcomes
   
3. Anyone planning to stop the medication — without adequate muscle, weight tends to return faster

How to protect your muscle while on GLP-1 medications

The research here is clear and consistent. A 2026 American College of Sports Medicine review pooling 137 research reviews covering more than 30,000 people found that training the major muscle groups approximately twice a week builds and maintains both muscle and strength. Second Nature

Four evidence-informed strategies:

1. Prioritize resistance training twice a week or more. Bodyweight exercises count — no gym required to start. Compound movements (squats, rows, push presses) recruit the most muscle tissue per session.
   
2. Eat enough protein. Most guidelines for people on weight-loss medications suggest 1.2–1.6g of protein per kilogram of body weight. Protein gives muscle the raw material to hold its position even in a caloric deficit.
   
3. Avoid losing weight too quickly. Aggressive restriction intensifies lean mass loss. A medically supervised program with gradual dose escalation typically produces a better body composition outcome than rushing to the highest dose.
   
4. Stay active — even moderately. Given the ENDO 2026 finding that GLP-1 users frequently become less active, intentional daily movement becomes more important, not less.

⚠️ Atention: This information is for general educational purposes. If you are on semaglutide or tirzepatide, or considering these medications, the guidance around dosing, nutrition, and exercise should be personalized by a licensed medical professional based on your health history. Individuals with pre-existing muscle-wasting conditions or osteoporosis require additional evaluation before starting GLP-1 therapy.

How Illusions Plastic Surgery supports patients on GLP-1s

At Illusions Plastic Surgery, our GLP-1 program combines monthly in-person medical evaluations with the oversight of Dr. James R. Lyons, MD — a plastic surgeon board-certified by the American Board of Plastic Surgery since 1986, with over 35 years of experience in surgery and body composition. That clinical background makes a concrete difference for patients on semaglutide or tirzepatide.

Muscle loss does not follow the same pattern in every patient. That is why each in-person visit serves to monitor how body composition is shifting, adjust the protocol when needed, and assess whether the patient’s trajectory is compatible with a future body contouring procedure — such as liposuction, a tummy tuck, or a Brazilian Butt Lift (BBL). This integration between clinical weight loss management and surgical planning is something few weight loss programs can offer with the same depth.

If you have been losing weight on GLP-1 injections and want to know whether your body is ready for the next step — or whether your current muscle baseline is where it needs to be — a consultation at our West Palm Beach clinic is where to start.